IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

International Application No.	:	PCT/DE99/01163
International Filing Date	:	15 APRIL 1999
U.S. Serial No.	:	09/673,840
Deposit Date U.S. Nat'l Phase	:	23 OCTOBER 2000
Priority Date(s) Claimed	:	21 APRIL 1998
Applicant(s)	:	SPECHT, Thomas, et al.

Title: HUMAN NUCLEIC ACID SEQUENCES OF NORMAL BLADDER TISSUE

PRELIMINARY AMENDMENT

Commissioner for Patents
Box PCT
Washington, D.C. 20231

Sir:

Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend as follows:

IN THE CLAIMS:

3. (Amended) Nucleic acid sequences Seq. ID Nos. 1-127 and 391-403 of claim 2, characterized in that they are expressed elevated in normal bladder tissue.

4. (Amended) BAC, PAC and cosmid clones containing functional genes and their chromosomal localization according to sequences Seq. ID Nos. 1-127 and 391-403 of claim 2 for use as vehicles for gene transfer.

5. (Amended) A nucleic acid sequence according to claim 1, wherein it has 90% homology to a human nucleic acid sequence.

6. (Amended) A nucleic acid sequence according to claim 1, wherein it has 95% homology to a human nucleic acid sequence.

7. (Amended) A nucleic acid sequence comprising a portion of the nucleic acid sequences named in claim 1, in such a sufficient amount that they hybridize with the sequences according to claim 1.

8. (Amended) A nucleic acid sequence according to claim 1, wherein the size of the fragment has a length of at least 50 to 4500 bp.

9. (Amended) A nucleic acid sequence according to claim 1, wherein the size of the fragment has a length of at least 50 to 4000 bp.

10. (Amended) A nucleic acid sequence according to claim 1, which codes at least one partial sequence of a bioactive polypeptide.

11. (Amended) An expression cassette, comprising a nucleic acid fragment or a sequence according to claim 1, together with at least one control or regulatory sequence.

13. (Amended) An expression cassette according to claim 11, wherein the DNA sequences located on the cassette code a fusion protein, which comprises a known protein and a bioactive polypeptide fragment.

14. (Amended) Use of nucleic acid sequences according to claim 1 for producing full-length genes.

16. (Amended) Host cell, containing as the heterologous part of its expressible genetic information a nucleic acid fragment according to claim 1.

18. (Amended) Host cell according to claim 16, wherein the prokaryotic cell system is E. coli, and the eukaryotic cell system is an animal, human or yeast cell system.

19. (Amended) A process for producing a polypeptide or a fragment, wherein the host cells according to claim 16 are cultivated.

27. (Amended) Use of polypeptide partial sequences according to sequences Seq. ID Nos. 128-390 and 404-431 of claim 23 as tools for finding active ingredients against the bladder tumor.

28. (Amended) Use of nucleic acid sequences according to sequences Seq. ID Nos. 1-127 and 391-403 of claim 2 for expression of polypeptides that can be used as tools for finding active ingredients against the bladder tumor.

29. (Amended) Use of nucleic acid sequences Seq. ID Nos. 1-127 and 391-403 of claim 2 in sense or antisense form.

30. (Amended) Use of polypeptide partial sequences Seq. ID Nos. 128-390 and 404-431 of claim 23 as pharmaceutical agents in gene therapy for treatment of the bladder tumor.

31. (Amended) Use of polypeptide partial sequences Seq. ID Nos. 128-390 and 404-431 of claim 23 for the production of a pharmaceutical agent for treatment of the bladder tumor.

32. (Amended) Pharmaceutical agent, containing at least one polypeptide partial sequence Seq. ID Nos. 128-390 and 404-431 of claim 23.

33. (Amended) A nucleic acid sequence according to claim 1, wherein it is a genomic sequence.

34. (Amended) A nucleic acid sequence according to claim 1, wherein it is an mRNA sequence.

35. (Amended) Genomic genes, their promoters, enhancers, silencers, exon structure, intron structure and their splice variants, that can be obtained from cDNAs of sequences Seq. ID Nos. 1-127 and 391-403 of claim 2.

38. (Amended) A nucleic acid sequence according to claim 1, wherein the size of the fragment has a length of at least 300 to 3500 bp.

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Respectfully submitted,

Anthony J. Zelano, Registration No. 27,969
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: 703-812-5311
Facsimile: 703-243-6410
Internet Address: zelano@mwzb.com

Filed: 6 MARCH 2001